Sign in

Gastric and oesophageal cancer: trials that stopped early

Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.

  1. Terminated

    BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

    Reason given in the registry

    “After the completion of phase IA, for business reasons it was decided to terminate the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Dec 2024.

    Ended
    Feb 2024
    Phase
    Phase 1/2
    Run by
    BioInvent International AB
    Registry record
    NCT05555251
  2. Terminated

    CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

    Reason given in the registry

    “for business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.

    Ended
    Feb 2024
    Phase
    Phase 1/2
    Run by
    Celularity Incorporated
    Registry record
    NCT05207722
  3. Withdrawn

    Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

    Reason given in the registry

    “Abandoned prior to launch.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Nov 2024.

    Run by
    Travera Inc
    Registry record
    NCT04985357
  4. Terminated

    A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

    Reason given in the registry

    “Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2024.

    Ended
    Nov 2023
    Phase
    Phase 2
    Run by
    Hoffmann-La Roche
    Registry record
    NCT04933227
  5. Terminated

    Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

    Reason given in the registry

    “slow recruitment forcing early suspension of screening and enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2024.

    Ended
    Nov 2023
    Phase
    Phase 2
    Run by
    Huazhong University of Science and Technology
    Registry record
    NCT04294784
  6. Terminated

    Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

    Reason given in the registry

    “Sponsor Termination”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Nov 2024.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    Molecular Templates, Inc.
    Registry record
    NCT06034860
  7. Suspended

    IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

    Reason given in the registry

    “Due to a business decision resulting in the deprioritization of this project and with no safety concerns present, we (the trial sponsor) have decided to request the discontinuation of study IMM2902-101.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2024.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    Registry record
    NCT05076591
  8. Terminated

    Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

    Reason given in the registry

    “Program terminated due to lack of meaningful efficacy signal.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Oct 2024.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    Inhibrx Biosciences, Inc
    Registry record
    NCT03809624
  9. Terminated

    A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

    Reason given in the registry

    “A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2024.

    Ended
    Aug 2024
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT05780736
  10. Terminated

    Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor

    Reason given in the registry

    “Not enough cases enrolled in the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Sept 2024
    Run by
    Peking University
    Registry record
    NCT02969122
  11. Terminated

    ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

    Reason given in the registry

    “Study was terminated due to difficulty recruiting subjects and lack of efficacy”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Sept 2024.

    Ended
    Dec 2023
    Phase
    Phase 2
    Run by
    Adaptimmune
    Registry record
    NCT04752358
  12. Terminated

    Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

    Reason given in the registry

    “Business Reason”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2024.

    Ended
    May 2024
    Phase
    Phase 2
    Run by
    LianBio LLC
    Registry record
    NCT06206278
  13. Terminated

    Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

    Reason given in the registry

    “PI left institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Johns Hopkins University
    Registry record
    NCT04583488
  14. Withdrawn

    Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

    Reason given in the registry

    “No enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2024.

    Ended
    Aug 2024
    Phase
    Phase 1/2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT05898828
  15. Terminated

    Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers

    Reason given in the registry

    “Futility”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jul 2024.

    Ended
    May 2024
    Run by
    Washington University School of Medicine
    Registry record
    NCT04072393
  16. Withdrawn

    Monopolar and Bipolar in Esophageal ESD

    Reason given in the registry

    “Study being withdrawn as it is re-written now as a prospective study. Please reference new study”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2024.

    Ended
    Jun 2024
    Run by
    Baylor College of Medicine
    Registry record
    NCT05736705
  17. Withdrawn

    GI Organ Tracking Via Balloon Applicators

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.

    Ended
    May 2025
    Run by
    Washington University School of Medicine
    Registry record
    NCT05471401
  18. Terminated

    Drainless Robot-assisted Minimally Invasive Esophagectomy

    Reason given in the registry

    “Following a safety analysis and assessment of the complications encountered by external experts, it was decided to terminate recruitment prematurely”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.

    Ended
    May 2024
    Run by
    Technische Universität Dresden
    Registry record
    NCT05553795
  19. Terminated

    The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.

    Reason given in the registry

    “recruiting issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 May 2024.

    Ended
    Dec 2023
    Phase
    Phase 4
    Run by
    Copenhagen University Hospital, Rigshospitalet
    Registry record
    NCT05354856
  20. Terminated

    Early Detection of Esophageal Cancer

    Reason given in the registry

    “Administratively closed by the IRBO”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 May 2024.

    Ended
    Apr 2024
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT00341523
  21. Withdrawn

    An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

    Reason given in the registry

    “The project is terminated”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Apr 2024.

    Ended
    Dec 2025
    Phase
    Early phase 1
    Run by
    Beijing Kejing Biotechnology Co., Ltd.
    Registry record
    NCT06284226
  22. Suspended

    DNX-2440 for Resectable Colorectal Liver Metastasis

    Reason given in the registry

    “DNAtrix management decision not based on study design, safety, or site performance.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2024.

    Phase
    Phase 1
    Run by
    DNAtrix, Inc.
    Registry record
    NCT04714983
  23. Terminated

    Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

    Reason given in the registry

    “Recruitment lower than expected and negative results.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Apr 2024.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Laval University
    Registry record
    NCT05687617
  24. Suspended

    Submucosal Tumor Removal by Endoscopic Excision Therapy

    Reason given in the registry

    “interim analysis”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Mar 2024.

    Ended
    Feb 2025
    Run by
    Universitätsklinikum Hamburg-Eppendorf
    Registry record
    NCT04913077
  25. Suspended

    A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

    Reason given in the registry

    “difficult in enrolling participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2024.

    Phase
    Phase 1/2
    Run by
    Shanghai Minimally Invasive Surgery Center
    Registry record
    NCT05101616
  26. Withdrawn

    INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

    Reason given in the registry

    “Due to the decision to discontinue the global clinical development program of tusamitamab ravtansine”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Feb 2024.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Erasmus Medical Center
    Registry record
    NCT05703555
  27. Suspended

    Upper GI Serial Tumour Biopsies

    Reason given in the registry

    “To explore alternative funding streams”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2024.

    Run by
    The Christie NHS Foundation Trust
    Registry record
    NCT05233007
  28. Terminated

    Prehabilitation in Esophageal Surgery (PRESS)

    Reason given in the registry

    “The study was terminated prematurely due to slow recruitment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2024.

    Ended
    Jan 2024
    Run by
    Università Vita-Salute San Raffaele
    Registry record
    NCT03798951
  29. Terminated

    LITT and Pembrolizumab in Recurrent Brain Metastasis

    Reason given in the registry

    “Sponsor terminated”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Dec 2023.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    University of Florida
    Registry record
    NCT04187872
  30. Terminated

    Systems Biology of Gastrointestinal and Related Diseases

    Reason given in the registry

    “Lack of enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2023.

    Ended
    Nov 2023
    Run by
    Viome
    Registry record
    NCT05579444

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.